

Hypertension & Left Ventricular Hypertrophy

Bibliography of One Hundred Key Papers

selected by **Enrico Agabiti-Rosei, MD, FESC; Maria Lorenza Muiesan, MD**
Internal Medicine - Medical and Surgical Sciences - University of Brescia - Brescia - ITALY

-
- | | |
|---|---|
| Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A, on behalf of the RACE Study Group. | <i>ACE-inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertension: results of the RACE (ramipril cardioprotective evaluation) study.</i>
J Hypertens. 1995;13:1325-1334. |
|---|---|
-
- | | |
|-------------------------------------|--|
| Agabiti Rosei E, Muiesan ML. | <i>Hypertension and diastolic function.</i>
Drugs. 1993;46(suppl 2):61-67. |
|-------------------------------------|--|
-
- | | |
|--|---|
| Agabiti-Rosei E, Muiesan ML, Trimarco B, Reid J, Hennig M, Zanchetti A. | <i>Changes of LV mass and ABPM during long-term antihypertensive treatment in ELSA.</i>
J Am Coll Cardiol. 2000;35:1760-1768. |
|--|---|
-
- | | |
|--|---|
| Appleton CP, Hatle LK, Popp RL. | <i>Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study.</i>
J Am Coll Cardiol. 1988;12:426-440. |
|--|---|
-
- | | |
|---|---|
| Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. | <i>Predictive value of systolic and diastolic function for incident congestive heart failure.</i>
J Am Coll Cardiol. 2001;37:1042-1048. |
|---|---|
-
- | | |
|---|---|
| Aurigemma GP, Silver HK, Priest MA, Gaasch WH. | <i>Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy.</i>
J Am Coll Cardiol. 1995;26:195-202. |
|---|---|
-
- | | |
|---|---|
| Badenhorst D, Veliotos D, Maseko M, et al. | <i>Adrenergic activation initiates chamber dilatation in concentric hypertrophy.</i>
Hypertension. 2003;41:499-504. |
|---|---|
-
- | | |
|---|---|
| Bella JN, Palmieri V, Liu JE, et al. | <i>Relationship between left ventricular diastolic relaxation and systolic function in hypertension. The Hypertension Genetic Epidemiology Network (HyperGEN) Study.</i>
Hypertension. 2001;38:424-434. |
|---|---|
-
- | | |
|--|--|
| Bella J, Palmieri V, Roman MJ, et al. | <i>Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults. The Strong Heart Study.</i>
Circulation. 2002;105:1928-1933. |
|--|--|
-

Bibliography of One Hundred Key Papers

- Bella J, Watchell K, Palmieri V, et al.** *Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study.*
J Hypertens. 2002;19:127-134.
-
- Bikkina M, Levy D, Evans JC, et al.** *Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study.*
JAMA. 1994;272:33-36.
-
- Blake J, Devereux RB, Herrold EM, et al.** *Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension.*
Am J Cardiol. 1988;62:246-252.
-
- Boeder WA, Noble NA.** *Transforming growth factor β in tissue fibrosis.*
N Engl J Med. 1994;331:1286-1292.
-
- Boluyt MO, O'Neill L, Meredith AL, et al.** *Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components.*
Circ Res. 1994;75:23-32.
-
- Bonow RO, Udelson JE.** *Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management.*
Ann Intern Med. 1992;117:502-510.
-
- Brilla CG, Funck RC, Rupp H.** *Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.*
Circulation. 2000;102:1388-1393.
-
- Brilla CG, Zhou G, Matsubara L, Weber KT.** *Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.*
J Mol Cell Cardiol. 1994;26:809-820.
-
- Brogan WCD, Hillis LD, Flores ED, Lange RA.** *The natural history of isolated left ventricular diastolic dysfunction.*
Am J Med. 1992;92:627-630.
-
- Capasso JM, Strobeck JF, Sonnenblick EH.** *Myocardial mechanical alterations during gradual onset long-term hypertension in rats.*
Am J Physiol. 1981;241:H435-H441.
-
- Casale PN, Devereux RB, Milner M, et al.** *Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men.*
Ann Int Med. 1986;105:173-178.
-
- Cruickshank JM, Lewis J, Moore V, Dodd A.** *Reversibility of left ventricular hypertrophy by differing types of anti-hypertensive therapy.*
J Hum Hypertens. 1992;6:85-90.
-
- Cuocolo A, Sax FL, Brush JE, Maron BJ, Bacharach SL, Bonow RO.** *Left ventricular hypertrophy and impaired diastolic filling in essential hypertension.*
Circulation. 1990;81:978-986.
-
- Cuspidi C, Lonati L, Sampieri L, et al.** *Left ventricular concentric remodelling and carotid structural changes in essential hypertension.*
J Hypertens. 1996;14:1441-1446.
-



- Cuspidi C, Marabini M, Lonati L, et al.** *Cardiac and carotid structure in patients with established hypertension and white-coat hypertension.* **J Hypertens.** 1995;13:1707-1711.
-
- Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Zanchetti. A on behalf of the CATCH investigators.** *Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.* **J Hypertens.** 2002;20:2293-2300.
-
- Dahlöf B, Pennert K, Hansson L.** *Reversal of Left Ventricular Hypertrophy in Hypertensive Patients. A Meta-analysis of 109 Treatment Studies.* **Am J Hypertens.** 1992;5:95-110.
-
- Dahlöf B, Zanchetti A, Diez J, et al, for the REGAAL Study Investigators.** *Effects of losartan and atenolol on left ventricular mass and neuro-hormonal profile in patients with essential hypertension and left ventricular hypertrophy.* **J Hypertens.** 2002;20:1855-1864.
-
- de Simone G, Devereux R, Celentano A, Roman MJ.** *Left ventricular chamber and wall mechanics in the presence of concentric geometry.* **J Hypertens.** 1999;17:1001-1006.
-
- de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH.** *Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension.* **Lancet.** 2004;363:1881-1891.
-
- de Simone G, Palmieri V, Koren M, Mensah G, Roman MJ, Devereux RB.** *Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension.* **J Hypertens.** 2001;19:119-125.
-
- Devereux RB.** *Hypertensive cardiac hypertrophy, pathophysiology and clinical characteristics. In: Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology, Diagnosis and Management. 2nd edition. New York, NY: Raven Press; 1995.*
-
- Devereux RB, Agabiti-Rosei E, Dahlöf B, et al.** *Regression of left ventricular hypertrophy is a surrogate end-point for morbid events in hypertension treatment trials.* **J Hypertens.** 1996;14(suppl 2):s95-s102.
-
- Devereux RB, Bella JN, Palmieri V, et al.** *Left ventricular systolic dysfunction in a biracial sample of hypertensive adults. The HyperGEN study.* **Hypertension.** 2001;38:417-423.
-
- Devereux RB, de Simone G, Pickering TG, Schwartz JE, Roman MJ.** *Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function.* **Hypertension.** 1998;31:929-936.
-
- Devereux RB, Palmieri V, Sharpe N, et al.** *Effects of once daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The prospective randomised enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial.* **Circulation.** 2001;104:1248-1254.
-
- Devereux RB, Roman MJ, Palmieri V, et al.** *Left ventricular wall stresses and wall stress-mass-heart-rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.* **J Hypertens.** 2000;18:1129-1138.

Bibliography of One Hundred Key Papers

-
- Devereux RB, Watchell K, Gerdtz E, et al.** *Regression of hypertensive left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial.*
J Hypertens. 2002;20(suppl 4):S5.
-
- Diamond JA, Krakoff LR, Goldman A, et al.** *Comparison of two calcium channel blockers on hemodynamics, left ventricular mass, and coronary vasodilatory response in advanced hypertension.*
Am J Hypertens. 2001;14:231-240.
-
- Edwards DR, Murphy G, Reynolds JJ, et al.** *TGF β modulates the expression of collagenase and metalloproteinase inhibitor.*
EMBO J. 1987;6:1899-1904.
-
- Everett AD, Tufro-McReddie A, Fisher A, Gomez RA.** *Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.*
Hypertension. 1994;23:587-592.
-
- Fagard RH.** *Reversibility of left ventricular hypertrophy by antihypertensive drugs.*
Neth J Med. 1995;47:173-179.
-
- Fagard R, Pardaens K.** *Left ventricular diastolic function predicts outcome in uncomplicated hypertension.*
Am J Hypertens. 2001;14:504-508.
-
- Frohlich E.** *Risk mechanisms in hypertensive heart disease.*
Hypertension. 1999;34(pt 2):782-789.
-
- Gardin JM, Drayer J, Weber M, et al.** *Doppler echocardiographic assessment of left ventricular systolic and diastolic function in mild hypertension.*
Hypertension. 1987;9:1190-1196.
-
- Gerdtz E, Bjornstad H, Toft S, Devereux RB, Omvik P.** *Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).*
J Hypertens. 2002;20:1223-1229.
-
- Gosse P, Sheridan DJ, Dubourg O, et al.** *Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the L.I.V.E. Study.*
J Hypertens. 2000;18:1465-1475.
-
- Gottdiener J, Reda D, Massie BM, Materson BJ.** *Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive agents.*
Circulation. 1997;95:2007-2014.
-
- Hanrath P, Mathey DG, Siegert R, Bleifeld W.** *Left ventricular relaxation and filling patterns in different forms of left ventricular hypertrophy: an echocardiographic study.*
Am J Cardiol. 1980;45:15-23.
-
- Hinderliter AL, Light KC, Willis PW IV.** *Patients with borderline elevated blood pressure have enhanced left ventricular contractility.*
Am J Hypertens. 1995;8:1040-1045.
-



-
- Hunt SA, Baker DW, Chin MH, et al.** ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the adult: executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and management Of Heart Failure). *J Am Coll Cardiol.* 2001;38:2101-2113.
-
- Inamura T, McDermott PJ, Kent RL, Nagatsu M, Cooper G, Carabello BA.** Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload. *Circ Res.* 1994;75:418-425.
-
- Ishikawa Y, Homcy CJ.** The adenylyl cyclases as integrators of transmembrane signal transduction. *Circ Res.* 1997;80:297-304.
-
- Jennings G, Wong J.** Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In: Hansonn L, Birkenhager WH, eds. **Handbook of Hypertension.** Vol 18. Assessment of hypertensive organ damage. Amsterdam, Netherlands: Elsevier Science BV; 1997:185-223.
-
- Kannel WB.** Prevalence and natural history of electrocardiographic left ventricular hypertrophy. *Am J Med.* 1983;75(suppl A):4-11.
-
- Kannel WB, Gordon T, Offutt D.** Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. *Ann Intern Med.* 1969;71:89-105.
-
- Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB.** Left ventricular mass changes during treatment and outcome in patients with essential hypertension. *Am J Hypertens.* 2002;15:1021-1028.
-
- Kozakowa M, Palombo C, Pratali L, Pittella G, Galetta F, L'Abbate A.** Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography. *Hypertension.* 1997;29:551-559.
-
- Levy D, Kenchaiah S, Larson MG, et al.** Long term trends in the incidence of and survival with heart failure. *N Engl J Med.* 2002;347:1397-1400.
-
- Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL.** The progression from hypertension to congestive heart failure. *JAMA.* 1996;275:1557-1562.
-
- Levy D, Salomon M, D'Agostino R, Belanger A, Kannel WB.** Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. *Circulation.* 1994;90:1786-1793.
-
- Liebson PR, Grandits GA, Dianzumba S, et al.** Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). *Circulation.* 1995;91:698-706.
-
- Little WC, Downes TR, Applegate RJ.** Invasive evaluation of left ventricular diastolic performance. *Herz.* 1990; 15:362-376.
-

Bibliography of One Hundred Key Papers

- Loaldi A, Pepi M, Agostoni PG, Guazzi M.** *Cardiac rhythm in hypertension assessed through 24-hour ambulatory electrocardiographic monitoring. Effect of load manipulation with atenolol, verapamil and nifedipine.*
Br Heart J. 1983;50:118-126.
-
- Lopez B, Querejeta R, Varo N, et al.** *Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.*
Circulation. 2001;104:286-291.
-
- Lorell BH, Carabello BA.** *Left ventricular hypertrophy pathogenesis, detection and prognosis.*
Circulation. 2000;102:470-479.
-
- Lucarini A, Picano E, Lattanzi F, et al.** *Dipyridamole echocardiography stress testing in hypertensive patients. Targets and tools.*
Circulation. 1991;83(suppl III):III68-III72.
-
- Lucarini A, Spessot M, Picano E, et al.** *Lack of correlation between cardiac mass and arteriolar structural changes in mild-to-moderate hypertension.*
J Hypertens. 1991;9:1187-1191.
-
- Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M,** *Effects of angiotensin blockade on coronary circulation and coronary reserve.*
Am J Med. 1988;84:55-60.
-
- Malmqvist K, Kahan T, Edner M, et al.** *Regression of left ventricular hypertrophy in human hypertension with irbesartan.*
J Hypertens. 2001;19:1167-1176.
-
- Mandinov L, Eberli FR, Seiler C, Hass OM.** *Diastolic heart failure.*
Cardiovasc Res. 2000;45:813-825.
-
- Mercadier JJ, de la Bastie D, Menasche P, et al.** *Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: a quantitative study.*
J Am Coll Cardiol. 1987;9:1024-1030.
-
- Molkentin JD.** *Calcineurin and beyond: cardiac hypertrophic signaling.*
Circ Res. 2000;87:731-738.
-
- Morgan HE, Baker KM.** *Cardiac hypertrophy.*
Circulation. 1991;83:13-25.
-
- Moser M, Hebert PR.** *Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.*
J Am Coll Cardiol. 1996;27:1214-1218.
-
- Motz W, Vogt M, Rabenau O, Scheler S, Luckoff A,** *Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms.*
Am J Cardiol. 1991;68:996-1003.
-
- Muiesan ML, Pasini GF, Salvetti M.** *Cardiac and vascular structural changes. Prevalence and relation to ambulatory blood pressure in a middle-aged general population in Northern Italy. The Vobarno Study.*
Hypertension. 1996;27:1046-1052.
-



-
- Muiesan ML, Rizzoni D, Zulli R, et al.** *Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension.*
J Hypertens. 1993;11(suppl 5):s300-s301.
-
- Muiesan ML, Rizzoni D, Salvetti A, et al.** *Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension.*
J Hypertens. 2002;20:1439-1446.
-
- Muiesan ML, Rizzoni D, Zulli R, Calebich S, Agabiti-Rosei E.** *Left ventricular systolic function during stress as related to impaired diastolic filling in essential hypertension.*
High Blood Press. 1992;1:287-295.
-
- Muiesan ML, Rizzoni D, Zulli R, et al.** *Cardiovascular characteristics in normotensive subjects with or without family history of hypertension.*
Clin Exp Hypertens. 1996;18:901-920.
-
- Muiesan ML, Salvetti M, Monteduro C, et al.** *Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.*
J Hypertens. 2000;18:1651-1656.
-
- Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.** *Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.*
J Hypertens. 1996;14(suppl 5):S43-S49.
-
- Nakajima H, Nakajima O, Salcher O, et al.** *Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta 1 transgene in the heart.*
Circ Res. 2000;86:571-579.
-
- Niteberg A, Anthony I.** *Epicardial coronary arteries are not adequately sized in hypertensive patients.*
J Am Coll Cardiol. 1996;27:115-123.
-
- Palatini P, Visentin P, Mormino P, et al, on behalf of the HARVEST Study group.** *Left ventricular performance in the early stages of systemic hypertension.*
Am J Cardiol. 1998;81:418-423.
-
- Palmieri V, Watchell K, Gerdtts E, et al.** *Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.*
Am Heart J. 2001;141:784-791.
-
- Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G.** *The smoothness index: a new reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension.*
J Hypertens. 1998;16:1685-1693.
-
- Pepi M, Alimento M, Maltagliati A, Guazzi M.** *Cardiac hypertrophy in hypertension: repolarization abnormalities elicited by rapid lowering of pressure.*
Hypertension. 1988;11:84-89.
-
- Perlini S, Muiesan ML, Cuspidi C, et al.** *Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.*
Circulation. 2001;103:678-683.
-

Bibliography of One Hundred Key Papers

- Pfeffer MA, Pfeffer JM.** *Cardiac hypertrophy in the spontaneously hypertensive rat: adaptation or primary myopathy? In: Tarazi RC, Dunbar JB, eds. Perspectives in Cardiovascular Research.* New York, NY: Raven Press; 1983;8:193.
-
- Pierdomenico SD, Lapenna D, Guglielmi MD, et al.** *Vascular changes in hypertensive patients with different left ventricular geometry.* **J Hypertens.** 1995;13:1701-1706.
-
- Pinto Y, Pinto-Sietsma SJ, Philipp T, et al.** *Reduction in left ventricular messenger RNA for transforming growth factor β 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in hypertensive TGR(mRen2)27 rats.* **Circulation.** 2000;36:747-754.
-
- Polese A, De Cesare N, Montorsi P, et al.** *Upward shift of the lower range of coronary autoregulation in hypertensive patients with hypertrophy of the left ventricle.* **Circulation.** 1991;83:845-853.
-
- Quinones MA, Otto C, Stoddard M, Waggoner A, Zoghbi W.** *Recommendations for quantifications of Doppler echocardiography: a report from the Doppler quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography.* **J Am Soc Echocardiogr.** 2002;15:167-184.
-
- Radice M, Alli C, Avanzino F, Di Tullio M, Mariotti G, Taioli E.** *Left ventricular structure and function in normotensive adolescents with a genetic predisposition to hypertension.* **Am Heart J.** 1986;111:115-120.
-
- Rakusan K, Flanagan MF, Geva T, Southern J, Van Praagh R.** *Morphometry of human coronary capillaries during normal growth and the effect of age on left ventricular pressure-overload hypertrophy.* **Circulation.** 1992;86:38-46.
-
- Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Roedeheffer RJ.** *Burden of systolic and diastolic ventricular dysfunction in the community.* **JAMA.** 2003;289:194-202.
-
- Rizzoni D, Muiesan ML, Porteri E, et al.** *Relations between cardiac and vascular structure in patients with primary and secondary hypertension.* **J Am Coll Cardiol.** 1998;32:985-992.
-
- Rizzoni D, Palombo C, Porteri E, et al.** *Relationship between coronary vasodilator capacity and small artery remodelling in hypertensive patients.* **J Hypertens.** 2003;21:615-621.
-
- Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB.** *Association of carotid atherosclerotic and left ventricular hypertrophy.* **J Am Coll Cardiol.** 1995;25:83-90.
-
- Rudic RD, Shesely EG, Meeda N, Smithies O, Segal SS, Sessa WC.** *Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodelling.* **J Clin Invest.** 1998;101:731-736.
-
- Sabbah NH.** *The cellular and physiological effects of beta-blockers in heart failure.* **Clin Cardiol.** 1999;22:16-20.
-



-
- Sadler DB, Aurigemma G, Williams D, Reda D, Materson B, Gottdiener J.** *Systolic function in hypertensive men with concentric remodeling.* **Hypertension.** 1997;30:777-781.
-
- Savage DD, Abbott RD, Anderson SJ, Padgett S.** *Determinants of left ventricular mass and reference values based on a large population-based sample of apparently healthy subjects: the Framingham Study.* **Circulation.** 1983;68(suppl III):111-136.
-
- Savage DD, Drayer Jim, Henry WM, et al.** *Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects.* **Circulation.** 1979;59:623-632.
-
- Schillaci G, Pasqualini L, Verdecchia P, et al.** *Prognostic significance of left ventricular diastolic dysfunction in essential hypertension.* **J Am Coll Cardiol.** 2002;39:2005-2011.
-
- Schillaci G, Vaudo G, Reboldi G, et al.** *High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension.* **J Hypertens.** 2001;19:2265-2270.
-
- Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Porcellati C.** *Early cardiac changes after menopause.* **Hypertension.** 1998;32:764-769.
-
- Shimuzu G, Zile MR, Blaustein AS, Gaasch WH.** *Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements.* **Circulation.** 1985;71:266-272.
-
- Sihm I, Schroeder AP, Aalkjær C, et al.** *The relation between peripheral vascular structure, left ventricular hypertrophy and ambulatory blood pressure in essential hypertension.* **Am J Hypertens.** 1995;8:987-996.
-
- Spann JF, Buccino RA, Sonnenblick EH, Braunwald E.** *Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure.* **Circ Res.** 1967;21:341-354.
-
- St John Sutton M.** *Mitral flow derived Doppler indices of left ventricular diastolic function.* **Eur Heart J.** 2000;21:1298-1300.
-
- Sun Y, Zhang JQ, Zhang J, Ramires FJ.** *Angiotensin II, transforming growth factor beta1 and repair in the infarcted heart.* **J Mol Cell Cardiol.** 1998;30:1559-1569.
-
- Tarazi RC, Frohlich ED.** *Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy?* **Circulation.** 1987;75(suppl I):I113-I117.
-
- Tarazi RC.** *Regression of left ventricular hypertrophy: partial answers for persistent questions.* **J Am Coll Cardiol.** 1984;3:1349-1351.
-
- Terpstra WF, May JF, Smit AJ, et al.** *Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial.* **J Hypertens.** 2001;19:303-309.
-

Bibliography of One Hundred Key Papers

- Thurmann P, Kenedi P, Schimdt A, Harder S, Rietbrock N.** *Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.*
Circulation. 1998;98:2037-2042.
-
- Vasan RS, Benjamin EJ, Levy D.** *Prevalence, clinical features and prognosis of diastolic heart failure, an epidemiological perspective.*
J Am Coll Cardiol. 1995;1565-1574.
-
- Vasan RS, Levy D.** *The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview.*
Arch Intern Med. 1996;156:1789-1796.
-
- Vatner SF, Hittinger L.** *Coronary vascular mechanisms involved in decompensation from hypertrophy to heart failure.*
J Am Coll Cardiol. 1993;22(suppl A):34A-40A.
-
- Vatner SF, Vatner DE, Homcy CJ.** *Beta-adrenergic receptor signaling: an acute compensatory adjustment-inappropriate for the chronic stress of heart failure. Insights from Gsa overexpression and other genetically engineered animal models.*
Circ Res. 2000;86:502-506.
-
- Verdecchia P, Schillaci G, Borgioni I, et al.** *Prognostic significance of serial changes in left ventricular mass in essential hypertension.*
Circulation. 1998;97:48-54.
-
- Verdecchia P, Schillaci G, Reboldi G, Ambrosio G, Pede S, Porcellati C.** *Prognostic value of midwall shortening fraction and its relation with left ventricular mass in systemic hypertension.*
Am J Cardiol. 2001;87:479-482.
-
- Weber KT, Brilla CG.** *Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system.*
Circulation. 1991;83:1849-1853.
-
- Weber KT, Eghbali M.** *Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy.*
Cardiovasc Rev Rep. 1991;12:61-69.
-

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide **title of manuscript** (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), **affiliations/address**, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International** (SI) units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher’s editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author’s responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

LEAD ARTICLE

The lead article should not exceed 25 standard typed pages (maximum 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 25 standard typed pages (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

FASCINOMA CARDIOLOGICA ARTICLES

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.